A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide (Wegovy®), are increasingly used for weight management in both adult and pediatric populations. Their mechanism of delayed gastric emptying raises concern for aspiration dur…
INTRODUCTION: Diabetes management involves using various oral hypoglycemic agents, including new glucagon-like peptide-1 (GLP-1) receptor agonists like semaglutide, tirzepatide, and liraglutide. Artificial intelligence (AI) tools such as ChatGPT (Ope…
BACKGROUND AND AIMS: The Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity (SELECT) trial demonstrated significant reductions in cardiovascular outcomes in people with cardiovascular disease (CVD) and overweight or o…
OBJECTIVE: In this case study conducted in a Danish general practice, we aimed to explore how patients with obesity experience a novel treatment approach: group consultations (GCs) for weight loss, lifestyle changes and semaglutide treatment. To rece…
Introduction This study aims to evaluate the risk of residual gastric content (RGC) among patients taking semaglutide/tirzepatide undergoing an esophagogastroduodenoscopy (EGD). Methods A retrospective observational study was conducted from 2024 to 2…
RATIONALE: Glucagon-like peptide-1 (GLP-1) receptor agonists reduce alcohol consumption in rodents and non-human primates. Semaglutide is a new long-acting GLP-1 receptor agonist, widely used in the clinic against type 2 diabetes and obesity. It is a…
INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for glycemic control and weight loss, but their effects on surgical outcomes remain incompletely understood. Delayed gastric emptying and associated perio…
This study introduces a novel dual-sensitive drug delivery system, gelatin-coated chitosan microparticles (GL-ChMPs), designed to enhance the lung targeting and therapeutic efficacy of semaglutide (SEM). GL-ChMPs were designed to respond to the acidi…
INTRODUCTION: This study compared the effectiveness of semaglutide 2.4 mg vs. no treatment with obesity medication (OM) for reducing weight and improving cardiometabolic risk factors among adults with obesity or overweight. METHODS: This real-world,…
Postmenopausal osteoporosis is a common chronic medical illness resulting from an imbalance between bone resorption and bone formation along with microarchitecture degeneration attributed to estrogen deficiency and often accompanied by other medical…
BACKGROUND: The FLOW clinical trial recently demonstrated that the glucagon-like peptide-1 receptor agonist once-weekly semaglutide 1 mg was associated with kidney- and cardio-protective effects (the latter already shown in the SUSTAIN 6 trial) compa…
OBJECTIVE: The objective of this study was to assess safety of once-weekly subcutaneous semaglutide 2.4 mg versus placebo, beyond reduction in major adverse cardiovascular events, in patients with established cardiovascular disease and overweight or…
OBJECTIVE: This study aimed to assess the effects of metformin (MET) monotherapy versus a combination of semaglutide and MET on weight, metabolism, reproductive function, and inflammatory markers in women with polycystic ovary syndrome (PCOS). METHOD…
Peripheral surgery evokes neuroimmune activation in the central nervous system and modulates immune cell polarization in the ischemic brain. However, the phenotypic change of microglia and myeloid cells within post-surgical ischemic brain tissue rema…
INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as an efficacious treatment for type 2 diabetes mellitus (T2DM) and have demonstrated substantial weight loss effects. This systematic review compares two prevalent GLP-1…
Heart failure with preserved ejection fraction (HFpEF) is associated with obesity, inflammation, and cardiac metabolism. While obesity contributes to HFpEF, the 'obesity paradox' suggests that higher BMI may correlate with better outcomes. Glucagon-l…
BACKGROUND: Type 2 diabetes mellitus (T2DM) is associated with cognitive dysfunction, which significantly impacts the quality of life. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has shown potential neuroprotective effects. This…